{"entity":{"id":"harbinger-resolve","kind":"drug","name":"RESOLVE (Harbinger Health)","aka":["Harbinger Health test","HarbingerHx"],"tldr":"Harbinger Health's blood test meant for the weeks between a doctor suspecting cancer and a diagnosis, pointing to where in the body a cancer may be; it is not offered as a screening test for well people.","summary":"Harbinger Health announced RESOLVE on 14 April 2026 as a new category aimed at the gap between suspicion of cancer and diagnosis, giving information on the cancer's tissue of origin, with first products expected to be commercially available in the second half of 2026 from its CLIA-certified, CAP-accredited laboratory. Whether it had launched by 29 October 2026 could not be confirmed.\n\nHarbinger's AACR 2026 posters (company release, 17 April 2026) describe a methylation-specific PCR assay at 97% specificity and a deep-learning model trained on more than 2,300 samples from the CORE-HH study (NCT05435066) that, at 98.5% specificity, raised sensitivity by 9.9 points overall, 6.5 at stage I and 17.6 at stage II; absolute figures were not given. No peer-reviewed paper and no number of cancer types were found. A prospective study, PROCARES (NCT07046260), is recruiting.","status":"emerging","asOf":"2026-10-29","links":[{"label":"Harbinger Health: RESOLVE announcement (14 April 2026)","url":"https://harbinger-health.com/harbinger-health-establishes-resolve-as-a-new-category-for-cancer-detection/"},{"label":"ClinicalTrials.gov NCT05435066","url":"https://clinicaltrials.gov/study/NCT05435066"},{"label":"ClinicalTrials.gov NCT07046260","url":"https://clinicaltrials.gov/study/NCT07046260"}],"tags":["test","mced","evidence:insufficient"],"related":[],"cancers":[],"sections":[],"technologies":["mced","liquid-biopsy","methylation-profiling"],"targets":[],"drugs":[],"companies":["harbinger-health"],"institutions":[],"pathways":[],"terms":[],"trials":["core-hh","procares"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Evidence grade insufficient: this is a diagnostic aid for people with symptoms, so the screening claim does not apply, and no peer-reviewed accuracy figure was found.","What a result means: a positive result is a reason for further tests, not a diagnosis; a negative result does not rule cancer out and does not replace the screening tests that have been shown to work (bowel, breast, cervical and, where eligible, lung screening)."],"brand":"RESOLVE","modality":"Multi-cancer blood test for people with suspected cancer (cell-free DNA methylation)","mechanism":"Cell-free DNA methylation read by a methylation-specific PCR assay and a deep-learning model, reporting a cancer signal and its tissue of origin.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/harbinger-resolve/","neighbours":{"technology":[{"id":"methylation-profiling","kind":"technology","name":"DNA methylation profiling","route":"/technologies/methylation-profiling/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"company":[{"id":"harbinger-health","kind":"company","name":"Harbinger Health","route":"/companies/harbinger-health/"}],"trial":[{"id":"core-hh","kind":"trial","name":"CORE-HH (Harbinger Health test development and validation)","route":"/trials/core-hh/"},{"id":"procares","kind":"trial","name":"PROCARES (Harbinger Health diagnostic aid in people with suspected cancer)","route":"/trials/procares/"}]}}